Alimera Sciences & Iluvien: A New Day

<p>In this episode, <strong>Rick Eiswirth,</strong> president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology.</p> <ul> <li>Intro <strong><em>:13</em></strong></li> <li>In this episode <strong><em>:18</em></strong></li> <li>About Rick Eiswirth <strong><em>:23</em></strong></li> <li>What’s your background? How did you get into the ophthalmology industry? <strong><em>0:51</em></strong></li> <li>What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? <strong><em>3:36</em></strong></li> <li>How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? <strong><em>6:26</em></strong></li> <li>Can you tell us more about the New Day trial? <strong><em>8:10</em></strong></li> <li>Which trial outcome would be considered a success for Iluvien? <strong><em>11:58</em></strong></li> <li>Do you anticipate a cost savings? <strong><em>13:58</em></strong></li> <li>What’s the status of the New Day trial? <strong><em>15:15</em></strong></li> <li>How has COVID changed the industry landscape in ophthalmology? <strong><em>16:20</em></strong></li> <li>Are there any new products in the pipeline? <strong><em>18:38</em></strong></li> <li>Iluvien is approved in other countries for uveitis <strong><em>20:36</em></strong></li> <li>What have you seen from retina specialists; are there longer efficacy rates? <strong><em>22:10</em></strong></li> <li>What do you think is the most important challenge the ophthalmic community will face in the future? <strong><em>23:17</em></strong></li> <li>Thanks for listening <strong><em>24:36</em></strong></li> </ul> <p><strong>Rick Eiswirth</strong> is president and CEO of Alimera Sciences.</p> <p>We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https: